Compare Fiverr International Ltd (FVRR) vs Vertex Pharmaceuticals Incorporated (VRTX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Fiverr International Ltd vs Vertex Pharmaceuticals Incorporated — how do they compare? Fiverr International Ltd trades at $8.76 (market cap $310.61M), while Vertex Pharmaceuticals Incorporated trades at $510.84 (market cap $127.55B). The key difference: Vertex Pharmaceuticals Incorporated is far larger — about 410.6× Fiverr International Ltd's market cap, and Vertex Pharmaceuticals Incorporated is trading nearer its 52-week high, Fiverr International Ltd nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Fiverr International Ltd for 62 Days and Vertex Pharmaceuticals Incorporated for 120 Days on average.
| FVRR | VRTX | |
|---|---|---|
Market Cap | $310.61M | $127.55B |
Volume | 381,459 | 1,487,944 |
Sector | Media | Health |
52-Week High | $23.60 | $557.96 |
52-Week Low | $8.47 | $407.37 |
Typical Hold Time | 62 Days | 120 Days |
Enterprise Value | $63.00M | $121.68B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Fiverr International (FVRR) trades at $8.70, up 2.35% on the day, but remains in a bearish technical trend with resistance near $9.00. Recent Q2 2026 earnings missed estimates, with revenue declining 10% year-over-year to $97.8 million, as AI adoption pressures lower-value freelance demand. The company maintains strong gross margins of 82% and trades at discounted valuations, including a P/E of 10.67 and P/S of 0.76. Cash flow trends show operational strength but negative net cash flow in 2025 and 2026.
The outlook is cautious; while valuations are low and profitability is improving, AI disruption and recent earnings misses pose significant headwinds. Analyst consensus is a 'Hold' with a $10.50 price target, reflecting near-term challenges but potential recovery if growth stabilizes. Key risks include competitive threats from AI tools and execution risks in adapting the business model.
Vertex Pharmaceuticals (VRTX) trades at $505.64, up 0.63% with mixed technical signals showing bearish moving averages but neutral oscillators. The company maintains strong fundamentals with $12B revenue, 35% net margin, and robust cash flow. Recent positive Phase 2b data for kidney drug inaxaplin and cystic fibrosis dominance support growth. Earnings show volatility with Q1 beat but Q2 miss against expectations.
Outlook remains positive with 84% analyst buy ratings and $573.50 consensus target offering 13% upside. Key risks include clinical trial outcomes, competitive pressures, and reliance on cystic fibrosis portfolio. The stock presents growth potential through pipeline expansion but faces sector volatility and execution challenges.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Fiverr International Ltd
Fiverr International Ltd is involved in buying and selling digital services in the same fashion as physical goods on an e-commerce platform. It is set out to design a digital marketplace that is built with a comprehensive SKU-like services catalog and a search, finds, and order process that mirrors a typical e-commerce transaction. The service offerings of the company include Graphics and Design, Digital Marketing, Writing and Translation, and Video and Animation among others.
Read more on FVRR →About Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals is a global biotechnology company that discovers and develops small-molecule drugs for the treatment of serious diseases. Its key drugs are Kalydeco, Orkambi, Symdeko, and Trikafta/Kaftrio for cystic fibrosis, where Vertex therapies remain the standard of care globally. In addition to its focus on cystic fibrosis, Vertex is diversifying its pipeline through gene-editing therapies such as CTX001 for beta-thalassemia and sickle-cell disease, small-molecule inhibitors targeting acute and chronic pain using non-opioid treatments, and small-molecule inhibitors of APOL1-mediated kidney diseases. Vertex is also investigating cell therapies to deliver a potential functional cure for type 1 diabetes.
Read more on VRTX →
